Commercial Health Insurances as an access route to the Chinese market
Commercial Health Insurances as an access route to the Chinese market
Published on PharmExec
China has historically been a challenging market for foreign healthcare manufacturers to achieve successful Pricing and Market Access (PM&A) outcomes for their drugs. The recent elimination of the Provincial Reimbursement Drug Lists (PRDL) has made the National Reimbursed Drugs List (NRDL) the sole route to public funding in China.
In a new article, published on Pharmexec, Anaïs Frappé, Amy Morgan and Crystal Leung, review market access opportunities in China through private payers, and how Commercial Health Insurance (CHI) can bring value before, during, and after NRDL inclusion. They focus on formulary-based health plans which require active engagement with stakeholders to achieve access, including city-based CHI, million-dollar CHI and specialty drug plans.
About the authors
Anaïs Frappé is a Principal at Windrose Consulting Group in London. She has over a decade of healthcare consulting experience in pricing & access, commercial, private equity, and org. strategy. Amy Morgan is Windrose’s Head of International Markets. She has over 20 years’ strategy consulting and P&MA experience in Emerging and Non-Traditional markets. The article also leveraged Crystal Leung’s (Senior Analyst at Windrose Consulting Group) support and knowledge.
Please get in touch if you would like to discuss Commercial Health Insurances as an access route to the Chinese market.